GILD · Gilead Sciences, Inc. · Financials
$145.58
-0.07 (-0.05%)
At close · Sep 10
Market Cap
$182.74B
Shares
1.24B
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$29.44B
+2.4%
FY2025
Net Income
$8.51B
+1672.9%
FY2025
Gross Margin
78.83%
+0.6pp
FY2025
Operating Margin
34.04%
+28.3pp
FY2025
Diluted EPS
$6.78
+1684.2%
FY2025
Operating Cash Flow
$10.02B
-7.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $30.46B | $29.44B | $28.75B | $27.12B | $27.28BG | $27.31B | $24.69B | $22.45B | $22.13B | $26.11B | $30.39B | $32.64B | $24.89B | $11.2B | $9.7B | $8.39B | $7.95B | $7.01B | $5.34B | $4.23B | |
| — | $6.22B | $6.23B | $6.25B | $6.5B | $5.66B | $6.6B | $4.57B | $4.68B | $4.85B | $4.37B | $4.26B | $4.01B | $3.79B | $2.86B | $2.47B | $2.12B | $1.87B | $1.6B | $1.13B | $768.77M | |
| — | $24.24B | $23.21B | $22.5B | $20.62B | $21.62B | $20.7B | $20.12B | $17.77B | $17.27B | $21.74B | $26.13B | $28.63B | $21.1B | $8.34B | $7.23B | $6.26B | $6.08B | $5.42B | $4.21B | $3.46B | |
| — | — | 78.83% | 78.26% | 76.04% | 79.26% | 75.82% | 81.48% | 79.18% | 78.07% | 83.26% | 85.98% | 87.73% | 84.78% | 74.48% | 74.53% | 74.67% | 76.48% | 77.24% | 78.87% | 81.83% | |
| — | $6.07B | $5.8B | $5.91B | $5.72B | $4.98B | $4.6B | $4.93B | $9.11B | $5.02B | $3.73B | $5.1B | $3.01B | $2.85B | $2.12B | $1.76B | $1.23B | $1.07B | $939.92M | $721.77M | $591.03M | |
| — | $6.52B | $5.77B | $6.09B | $6.09B | $5.67B | $5.25B | $5.15B | $4.38B | $4.06B | $3.88B | $3.4B | $3.43B | $2.98B | $1.7B | $1.46B | $1.24B | $1.04B | $946.69M | $797.34M | $705.74M | |
| — | — | $2.4B | $2.4B | $2.3B | $1.8B | $1.7B | $1.2B | — | — | — | — | — | — | — | $63.3M | $69.6M | $59.9M | — | — | — | |
| — | $108M | $138M | $188M | $527M | — | — | — | — | — | — | — | — | — | — | $15.13M | $0 | — | — | — | — | |
| — | $32.95B | $19.42B | $27.09B | $19.51B | $19.95B | $17.39B | $20.62B | $18.16B | $13.93B | $11.98B | $12.76B | $10.45B | $9.63B | $6.68B | $5.69B | $4.6B | $3.99B | $3.48B | $2.66B | $2.07B | |
| — | -$2.5B | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B | $4.29B | $8.2B | $14.12B | $17.63B | $22.19B | $15.27B | $4.52B | $4.01B | $3.79B | $3.96B | $3.53B | $2.68B | $2.16B | |
| — | — | 34.04% | 5.78% | 28.05% | 26.87% | 36.32% | 16.49% | 19.1% | 37.06% | 54.1% | 58.02% | 68% | 61.33% | 40.39% | 41.33% | 45.2% | 49.84% | 50.34% | 50.2% | 51.17% | |
| — | $997M | $1.02B | $977M | $944M | $935M | $1B | $984M | $995M | $1.08B | $1.12B | $964M | $688M | $412M | $307M | $361M | $205.42M | $108.96M | $69.66M | $65.24M | $63.18M | |
| — | $1.54B | $798M | $6M | $198M | -$581M | -$639M | -$1.42B | $1.87B | $676M | $523M | $428M | $154M | $3M | -$9M | -$37M | $66.58M | $60.29M | $42.4M | $59.4M | $109.82M | |
| — | -$1.96B | $9.8B | $690M | $6.86B | $5.81B | $8.28B | $1.67B | $5.16B | $7.8B | $13.53B | $17.1B | $21.66B | $14.86B | $4.21B | $3.61B | $3.65B | $3.91B | $3.5B | $2.67B | $2.21B | |
| — | $1.29B | $1.29B | $211M | $1.25B | $1.25B | $2.08B | $1.58B | -$204M | $2.34B | $8.89B | $3.61B | $3.55B | $2.8B | $1.15B | $1.04B | $861.95M | $1.02B | $876.36M | $702.36M | $635.36M | |
| — | -$3.24B | $8.51B | $480M | $5.67B | $4.59B | $6.23B | $123M | $5.39B | $5.46B | $4.63B | $13.5B | $18.11B | $12.1B | $3.08B | $2.59B | $2.8B | $2.9B | $2.64B | $1.98B | $1.58B | |
| — | — | 28.9% | 1.67% | 20.89% | 16.83% | 22.8% | 0.5% | 23.99% | 24.65% | 17.73% | 44.43% | 55.48% | 48.62% | 27.45% | 26.71% | 33.43% | 36.5% | 37.59% | 37.09% | 37.47% | |
| — | — | $0 | $0 | -$52M | -$26M | -$24M | -$34M | -$22M | $5M | $16M | -$13M | -$2M | -$42M | -$18M | -$18M | -$14.58M | -$11.51M | $10.16M | -$8.56M | -$9.11M | |
| — | -$3.13B | $8.42B | $584M | $5.69B | $4.51B | $6.37B | -$22M | $5.39B | $5.66B | $4.52B | $13.69B | $17.9B | $12.53B | $3B | $2.49B | $2.83B | $2.94B | $2.58B | $2.02B | $1.57B | |
| USD/shares | — | -$2.61 | $6.84 | $0.38 | $4.54 | $3.66 | $4.96 | $0.10 | $4.24 | $4.20 | $3.54 | $10.08 | $12.37 | $7.95 | $2.01 | $1.71 | $1.81 | $1.69 | $2.91 | $2.15 | $1.71 |
| USD/shares | $-3.75 – $-3.40 | -$2.66 | $6.78 | $0.38G | $4.50 | $3.64G | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 | $11.91 | $7.35 | $1.81 | $1.64 | $1.77 | $1.66 | $2.82 | $2.06 | $1.64 |
| shares | — | — | 1.24B | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.27B | 1.3B | 1.31B | 1.34B | 1.46B | 1.52B | 1.53B | 1.52B | 1.55B | 1.71B | 904.6M | 920.69M | 929.13M |
| shares | — | — | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B | 1.52B | 1.65B | 1.7B | 1.58B | 1.58B | 1.75B | 934.11M | 958.83M | 964.36M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $50.66B in buybacks, $35.75B in dividends.
Debt Profile
Completed filing coverage through Apr 28, 2026Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
6.76×
Peer median 6.54×
EV/EBIT
—
P/E (TTM)
—
Peer median 36.55×
Peer medians compare against the 8 similar-size Drug Manufacturers - General companies (of 13 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $20,876,000,000 | $20,591,000,000 | $19,438,000,000 | $18,884,000,000 | $19,267,000,000 | $18,217,000,000 | $16,645,000,000 | $16,269,000,000 |
| Europe | $5,064,000,000 | $4,634,000,000 | $4,310,000,000 | $4,469,000,000 | $4,874,000,000 | $4,135,000,000 | $3,811,000,000 | $4,006,000,000 |
| Rest of World | $3,503,000,000 | $3,529,000,000 | $3,368,000,000 | $3,928,000,000 | — | — | — | — |
| Other International | — | — | — | — | $3,164,000,000 | $2,337,000,000 | $1,993,000,000 | $1,852,000,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $28,915,000,000 | $28,610,000,000 | $26,934,000,000 | $26,982,000,000 | $27,008,000,000 | $24,355,000,000 | $22,119,000,000 | $21,677,000,000 |
| HIV Product Sales | $20,752,000,000 | $19,612,000,000 | $18,175,000,000 | $17,194,000,000 | $16,315,000,000 | $16,938,000,000 | $16,438,000,000 | $14,627,000,000 |
| HIV Products Biktarvy | $14,334,000,000 | $13,423,000,000 | $11,850,000,000 | $10,390,000,000 | $8,624,000,000 | $7,259,000,000 | $4,738,000,000 | $1,184,000,000 |
| Oncology Product | $3,236,000,000 | $3,289,000,000 | $2,932,000,000 | $2,139,000,000 | $1,251,000,000 | — | — | — |
| Liver Disease | $3,217,000,000 | $3,021,000,000 | $2,784,000,000 | $2,798,000,000 | $2,850,000,000 | — | — | — |
| HIV Products Descovy | $2,758,000,000 | $2,113,000,000 | $1,985,000,000 | $1,872,000,000 | $1,700,000,000 | $1,861,000,000 | $1,500,000,000 | $1,581,000,000 |
| Cell Therapy Products Total Cell Therapy Product Sales | $1,839,000,000 | $1,973,000,000 | $1,869,000,000 | $1,459,000,000 | $871,000,000 | $607,000,000 | $456,000,000 | $264,000,000 |
| HIV Products Genvoya | $1,498,000,000 | $1,762,000,000 | $2,060,000,000 | $2,404,000,000 | $2,879,000,000 | $3,338,000,000 | $3,931,000,000 | $4,624,000,000 |
| Other Products Yescarta | $1,495,000,000 | $1,570,000,000 | $1,498,000,000 | $1,160,000,000 | $695,000,000 | $563,000,000 | $456,000,000 | $264,000,000 |
| Trodelvy | $1,397,000,000 | $1,315,000,000 | $1,063,000,000 | $680,000,000 | $380,000,000 | $49,000,000 | $0 | — |
| Liver Disease Products Sofosbuvir Velpatasvir | $1,272,000,000 | $1,596,000,000 | $1,537,000,000 | $1,530,000,000 | — | — | — | — |
| HIV Products Odefsey | $1,167,000,000 | $1,288,000,000 | $1,350,000,000 | $1,469,000,000 | $1,568,000,000 | $1,672,000,000 | $1,655,000,000 | $1,598,000,000 |
| Liver Disease Products Vemlidy | $1,070,000,000 | $959,000,000 | $862,000,000 | $842,000,000 | — | — | — | — |
| Veklury | $911,000,000 | $1,799,000,000 | $2,184,000,000 | $3,905,000,000 | $5,565,000,000 | $2,811,000,000 | $0 | — |
| Liver Disease Products Other Liver Disease | $874,000,000 | $467,000,000 | $385,000,000 | $426,000,000 | — | — | — | — |
| Other Products Total Other Product Sales | $799,000,000 | $889,000,000 | $859,000,000 | $946,000,000 | $1,027,000,000 | $1,026,000,000 | $1,547,000,000 | $3,100,000,000 |
| Royalty Contract and Other | $527,000,000 | $144,000,000 | $182,000,000 | $299,000,000 | $297,000,000 | $334,000,000 | $330,000,000 | $450,000,000 |
| Other Products AmBisome | $509,000,000 | $533,000,000 | $492,000,000 | $497,000,000 | $540,000,000 | $436,000,000 | $407,000,000 | $420,000,000 |
| HIV Products Other HIV | $500,000,000 | $434,000,000 | $401,000,000 | $530,000,000 | — | — | — | — |
| HIV Products Symtuza Revenue Share | $495,000,000 | $592,000,000 | $529,000,000 | $530,000,000 | — | — | — | — |
| Cell Therapy Products Tecartus | $344,000,000 | $403,000,000 | $370,000,000 | $299,000,000 | $176,000,000 | $44,000,000 | $0 | — |
| Other Products Other | $290,000,000 | $356,000,000 | $367,000,000 | $449,000,000 | $281,000,000 | $276,000,000 | $203,000,000 | $218,000,000 |
| Call Therapy Products Tecartus | — | — | — | — | — | $44,000,000 | $0 | $0 |
| COVID-19 Products Trodelvy | — | — | — | — | — | $49,000,000 | $0 | $0 |
| COVID-19 Products Veklury | — | — | — | — | — | $2,811,000,000 | $0 | $0 |
| HCV Product Sales | — | — | $1,767,000,000 | $1,810,000,000 | $1,881,000,000 | $2,064,000,000 | $2,936,000,000 | $3,686,000,000 |
| HCV Products Ledipasvir Sofosbuvir | — | — | $70,000,000 | $115,000,000 | $212,000,000 | $272,000,000 | $643,000,000 | $1,222,000,000 |
| HCV Products Sofosbuvir Velpatasvir | — | — | $1,537,000,000 | $1,530,000,000 | $1,462,000,000 | $1,599,000,000 | $1,965,000,000 | $1,966,000,000 |
| HCV Products Vosevi | — | — | — | — | — | — | $257,000,000 | $396,000,000 |
| Hepatitis B Virus Hepatitis Delta Virus Product | — | — | $1,017,000,000 | $988,000,000 | $969,000,000 | $860,000,000 | $742,000,000 | — |
| Hepatitis B Virus Hepatitis Delta Virus Product Other | — | — | $72,000,000 | $55,000,000 | $44,000,000 | $18,000,000 | $11,000,000 | — |
| Hepatitis B Virus Hepatitis Delta Virus Product Vemlidy | — | — | $862,000,000 | $842,000,000 | $814,000,000 | $657,000,000 | $488,000,000 | — |
| Hepatitis B Virus Hepatitis Delta Virus Product Viread | — | — | $83,000,000 | $91,000,000 | $111,000,000 | $185,000,000 | $243,000,000 | — |
| HIV Products Atripla | — | — | — | — | $145,000,000 | $349,000,000 | $600,000,000 | $1,206,000,000 |
| HIV Products Complera Eviplera | — | — | $129,000,000 | $200,000,000 | $258,000,000 | $269,000,000 | $406,000,000 | $653,000,000 |
| HIV Products Stribild | — | — | $101,000,000 | $127,000,000 | $189,000,000 | $196,000,000 | $369,000,000 | $644,000,000 |
| HIV Products Truvada | — | — | $114,000,000 | $147,000,000 | $371,000,000 | $1,448,000,000 | $2,813,000,000 | $2,997,000,000 |
| Other HCV | — | — | $160,000,000 | $166,000,000 | $207,000,000 | $193,000,000 | $328,000,000 | $498,000,000 |
| Other Products Letairis | — | — | $142,000,000 | $196,000,000 | $206,000,000 | $314,000,000 | $618,000,000 | $943,000,000 |
| Other Products Ranexa | — | — | — | — | $10,000,000 | $9,000,000 | $216,000,000 | $758,000,000 |
| Other Products Vemlidy | — | — | — | — | — | $657,000,000 | $488,000,000 | $321,000,000 |
| Other Products Viread | — | — | — | — | — | $185,000,000 | $243,000,000 | $307,000,000 |
| Other Products Zydelig | — | — | — | — | $62,000,000 | $72,000,000 | $103,000,000 | $133,000,000 |
| Products Other HIV | — | — | $56,000,000 | $57,000,000 | $195,000,000 | $407,000,000 | $47,000,000 | $61,000,000 |
| Products Revenue Share Symtuza | — | — | $529,000,000 | $530,000,000 | $531,000,000 | $488,000,000 | $379,000,000 | $79,000,000 |
Key facts
CIK
882095
CUSIP
375558103
13F (30d)
828 filings
788 filers
Visit website
Investor relations